You are hereJune 3, 2020
'Cord Blood Connect' Will Be Virtual in 2020
Travel unnecessary to attend, learn and connect at this year's international congress
During challenging times, it’s more important than ever to stay connected and share information. Yet the risks to health and safety are just too great for an in-person Cord Blood Connect during a worldwide pandemic.
These are factors in a CBA Board of Directors decision to transform this year’s international congress into an online event.
“As excited as we were about a robust, memorable in-person congress this September in Miami Beach, concerns for the health and safety for our attendees, faculty, exhibitors and staff outweighed all other considerations,” said CBA President Joanne Kurtzberg, MD. “So many things related to the COVID-19 pandemic remain unknown, not the least being the status of the contagion in September.”
The challenge now is to re-imagine and re-engineer the event to take advantage of some benefits of an online platform, such as potentially greater reach. Participation won’t be limited by long-distance travel time or costs, so more people can attend the congress, perhaps for the first time.
Contingency planning for a virtual congress, under way since March, has been especially brisk in recent weeks. In the coming days, decisions will be finalized as to the dates for the event, session topics, faculty, abstract submission, exhibits, registration and myriad other details.
Look for information that will be communicated as soon as it becomes available.
Cord Blood Inventories Safe and Readily Available
Answers provided about cord blood and perinatal tissue banking during the pandemic
The Cord Blood Association has prepared answers to frequently asked questions about cord blood and perinatal tissue banking during the coronavirus pandemic. The questions generally center on the safety of current inventories, collections during the pandemic, and cord blood as an alternative when a matched living donor is unavailable for a transplant patient.
There’s also the intriguing question about whether cord blood, cord tissue or placenta tissue might be used in the manufacture of cell therapies to fight the COVID-19 virus.